Valeant to acquire Dow Pharmaceuticals

US-based Valeant Pharmaceuticals International has agreed to acquire Dow Pharmaceutical Sciences, a privately held US dermatology company, for $285 million (£190 million)

Marc Barber

Marc Barber

Marc was editor of GrowthBusiness from 2006 to 2010. He specialised in writing about entrepreneurs, private equity and venture capital, mid-market M&A, small caps and high-growth businesses.

Related Topics

Early Stage Funding